<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00763997</url>
  </required_header>
  <id_info>
    <org_study_id>NRA3480005</org_study_id>
    <nct_id>NCT00763997</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Dipyrone, Ibuprofen, Paracetamol and Parecoxib on the Platelet Aggregation in Analgetic Dosages</brief_title>
  <official_title>Study of the Effect of Dipyrone, Ibuprofen, Paracetamol and Parecoxib on the Platelet Aggregation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruhr University of Bochum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dipyrone is suggested to inhibit the platelet aggregation comparable to th effect of
      traditional analgetic substances like Ibuprofen. To verify this hypothesis the investigators
      conducted the study in comparing patients undergoing traumatologic, visceral or plastic
      surgical procedures. The investigators randomized them to four groups receiving common
      analgetic doses of either dipyrone, acetaminophen (paracetamol) or valdecoxib/parecoxib. The
      investigators took blood samples before initiation of the study drug, 1h, 4hs and 24hs after
      first intake. The investigators compared the aggregation via aggregometry of platelet rich
      plasma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of aggregation in platelet rich plasma fter 24 hours of treatment with analgetic doses</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of aggregation of platelet rich plasma 1hour and 4 hours after initiation of study drug</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Platelet Aggregation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dipyrone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetaminophen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Parecoxib/Valdecoxib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dipyrone</intervention_name>
    <description>Dipyrone is given in the operation room with 2,5 g intravenously, followed by an oral regime of 4x1g on the ward</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen is given orally 600mg in the Post Anesthesia Care Unit, followed by an oral regime of 800mg twice a day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Acetaminophen is given 1g intravenously in the Operation room, followed by an oral regime of 1g fourth a day</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Acetaminophen is given 1g intravenously in the operation room, followed by 1g orally fourth a day</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parecoxib/Valdecoxib</intervention_name>
    <description>40mg Parecoxib are given intravenously in the operation room, followed by 40mg of Valdecoxib orally twice a day</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Blood samples for aggregometry are taken before induction of anesthesia, 1h after first drug intake, 4hs and 24hs after first intake</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned traumatologic, orthopedic, visceral or plastic surgical procedures

        Exclusion Criteria:

          -  Prior intake of drugs with effect on the platelet aggregation

          -  Patients with diseases of the gastrointestinal systems

          -  Patients with cardiac or circulatory diseases

          -  Patients receiving corticoids

          -  Patients with cold or asthma

          -  ASA-classification &gt; 3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Schmauss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>research associate of the Ruhr University Bochum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph Maier, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Leader of the Department for Pain Medicine of the University Hospital Bergmannsheil Bochum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BG University Hospital Bergmannsheil GmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2008</study_first_submitted>
  <study_first_submitted_qc>September 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2008</study_first_posted>
  <last_update_submitted>September 29, 2008</last_update_submitted>
  <last_update_submitted_qc>September 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Matthias Schmau√ü</name_title>
    <organization>MD, scientific associate with the Ruhr Unievrsity Bochum</organization>
  </responsible_party>
  <keyword>dipyrone</keyword>
  <keyword>platelet aggregation</keyword>
  <keyword>neuraxial blockage</keyword>
  <keyword>ibuprofen</keyword>
  <keyword>platelet aggregation under dipyrone compared to ibuprofen, acetaminophen and parecoxib/valdecoxib</keyword>
  <keyword>neuraxial blockage in patients receiving ibuprofen is critical in special circumstances, but traditionally not fpr dipyrone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Parecoxib</mesh_term>
    <mesh_term>Valdecoxib</mesh_term>
    <mesh_term>Dipyrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

